Cargando…
Efficacy of amlodipine besylate and Valsartan for the treatment of mild to moderate hypertension
BACKGROUND: Clinical researchers found that Amlodipine besylate and Valsartan (ABVS) can effectively treat mild to moderate hypertension (MMH). However, no study has systematically investigated its efficacy and safety for patients with MMH. Thus, present study will systematically assess the efficacy...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6616441/ https://www.ncbi.nlm.nih.gov/pubmed/31261595 http://dx.doi.org/10.1097/MD.0000000000016264 |
_version_ | 1783433508921802752 |
---|---|
author | Wang, Xiao-ou Tian, Wen |
author_facet | Wang, Xiao-ou Tian, Wen |
author_sort | Wang, Xiao-ou |
collection | PubMed |
description | BACKGROUND: Clinical researchers found that Amlodipine besylate and Valsartan (ABVS) can effectively treat mild to moderate hypertension (MMH). However, no study has systematically investigated its efficacy and safety for patients with MMH. Thus, present study will systematically assess the efficacy and safety of ABVS for patients with MMH. METHODS: MEDICINE, Cochrane Library, EMBASE, Ovid, PsycINFO, Web of Science, Allied and Complementary Medicine Database, and China National Knowledge Infrastructure will be searched for literatures related to the topic from inception to the present without language limitations. All randomized controlled trials that assess the efficacy and safety of ABVS for patients with MMH will be considered for inclusion. Two researchers will independently select study, extract data, and assess risk of bias for all eligible studies. RESULTS: The primary outcome includes the change of seated diastolic blood pressure. The secondary outcomes consist of the change of seated systolic blood pressure, health-related quality of life, and the tolerability. CONCLUSIONS: The results of this study will summarize the latest evidence on ABVS for the treatment of MMH. ETHICS AND DISSEMINATION: This study does not need ethical approval, because it will not use individual data. The results of this study are expected to be published at peer-reviewed journals. PROSPERO REGISTRATION NUMBER: PROSPERO CRD42019133123. |
format | Online Article Text |
id | pubmed-6616441 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-66164412019-07-22 Efficacy of amlodipine besylate and Valsartan for the treatment of mild to moderate hypertension Wang, Xiao-ou Tian, Wen Medicine (Baltimore) Research Article BACKGROUND: Clinical researchers found that Amlodipine besylate and Valsartan (ABVS) can effectively treat mild to moderate hypertension (MMH). However, no study has systematically investigated its efficacy and safety for patients with MMH. Thus, present study will systematically assess the efficacy and safety of ABVS for patients with MMH. METHODS: MEDICINE, Cochrane Library, EMBASE, Ovid, PsycINFO, Web of Science, Allied and Complementary Medicine Database, and China National Knowledge Infrastructure will be searched for literatures related to the topic from inception to the present without language limitations. All randomized controlled trials that assess the efficacy and safety of ABVS for patients with MMH will be considered for inclusion. Two researchers will independently select study, extract data, and assess risk of bias for all eligible studies. RESULTS: The primary outcome includes the change of seated diastolic blood pressure. The secondary outcomes consist of the change of seated systolic blood pressure, health-related quality of life, and the tolerability. CONCLUSIONS: The results of this study will summarize the latest evidence on ABVS for the treatment of MMH. ETHICS AND DISSEMINATION: This study does not need ethical approval, because it will not use individual data. The results of this study are expected to be published at peer-reviewed journals. PROSPERO REGISTRATION NUMBER: PROSPERO CRD42019133123. Wolters Kluwer Health 2019-06-28 /pmc/articles/PMC6616441/ /pubmed/31261595 http://dx.doi.org/10.1097/MD.0000000000016264 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 |
spellingShingle | Research Article Wang, Xiao-ou Tian, Wen Efficacy of amlodipine besylate and Valsartan for the treatment of mild to moderate hypertension |
title | Efficacy of amlodipine besylate and Valsartan for the treatment of mild to moderate hypertension |
title_full | Efficacy of amlodipine besylate and Valsartan for the treatment of mild to moderate hypertension |
title_fullStr | Efficacy of amlodipine besylate and Valsartan for the treatment of mild to moderate hypertension |
title_full_unstemmed | Efficacy of amlodipine besylate and Valsartan for the treatment of mild to moderate hypertension |
title_short | Efficacy of amlodipine besylate and Valsartan for the treatment of mild to moderate hypertension |
title_sort | efficacy of amlodipine besylate and valsartan for the treatment of mild to moderate hypertension |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6616441/ https://www.ncbi.nlm.nih.gov/pubmed/31261595 http://dx.doi.org/10.1097/MD.0000000000016264 |
work_keys_str_mv | AT wangxiaoou efficacyofamlodipinebesylateandvalsartanforthetreatmentofmildtomoderatehypertension AT tianwen efficacyofamlodipinebesylateandvalsartanforthetreatmentofmildtomoderatehypertension |